Chengdu, China

Xiawei Wei

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 3.9

ph-index = 1


Location History:

  • Chengdu, CN (2020 - 2021)
  • Chengdu Tianfu International Bio-Town, CN (2023)

Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xiawei Wei

Introduction

Xiawei Wei is a prominent inventor based in Chengdu, China, known for his significant contributions to the field of pharmaceutical sciences. With a total of five patents to his name, Wei has made remarkable advancements in the delivery of nucleic acids and the development of pharmaceutical compounds.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Ionizable lipids and compositions for nucleic acid delivery." This patent describes a compound that can be incorporated into lipid particles for the effective delivery of active agents, such as nucleic acids. Another notable patent is "Application of monocyclic β-lactam compound in pharmacy," which outlines the use of a specific compound in the preparation of drugs aimed at treating pneumonia.

Career Highlights

Xiawei Wei has worked with several reputable companies, including Westgene Biopharma Co., Ltd and Shenzhen Optimum Biological Technology Co., Ltd. His work in these organizations has contributed to the advancement of biopharmaceutical technologies and innovative drug delivery systems.

Collaborations

Wei has collaborated with notable colleagues, including Yuquan Wei and Jian Li, further enhancing his research and development efforts in the pharmaceutical industry.

Conclusion

Xiawei Wei's innovative work and patents have significantly impacted the field of drug delivery and pharmaceutical development. His contributions continue to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…